# Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN

> **NCT04034225** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sensei Biotherapeutics, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** SNS-301
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04034225
- **Lead sponsor:** Sensei Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-11
- **Primary completion:** 2021-06-28
- **Final completion:** 2021-06-28
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Terminated by the sponsor
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04034225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04034225, "Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04034225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*